Medlive Technology Co., Ltd.

SEHK:2192 Stock Report

Market Cap: HK$4.7b

Medlive Technology Future Growth

Future criteria checks 2/6

Medlive Technology is forecast to grow earnings and revenue by 6% and 15.2% per annum respectively. EPS is expected to grow by 3.4% per annum. Return on equity is forecast to be 3.2% in 3 years.

Key information

6.0%

Earnings growth rate

3.4%

EPS growth rate

Healthcare Services earnings growth30.6%
Revenue growth rate15.2%
Future return on equity3.2%
Analyst coverage

Low

Last updated02 Jan 2024

Recent future growth updates

Recent updates

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Earnings and Revenue Growth Forecasts

SEHK:2192 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266521781761831
12/31/20255851521481542
12/31/20244871211301352
12/31/202339716673782
6/30/20233561896979N/A
3/31/20233351536978N/A
12/31/20223141177077N/A
9/30/2022300835157N/A
6/30/2022286483236N/A
3/31/2022285443740N/A
12/31/2021284414244N/A
9/30/2021270557173N/A
6/30/202125570100101N/A
3/31/202123478105106N/A
12/31/202021485110111N/A
12/31/2019122312628N/A
12/31/201883141922N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2192's forecast earnings growth (6% per year) is above the savings rate (2%).

Earnings vs Market: 2192's earnings (6% per year) are forecast to grow slower than the Hong Kong market (13% per year).

High Growth Earnings: 2192's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2192's revenue (15.2% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).

High Growth Revenue: 2192's revenue (15.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2192's Return on Equity is forecast to be low in 3 years time (3.2%).


Discover growth companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.